The 6 most recent market catalysts affecting $CRSP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 85
CRISPR Therapeutics shares are trading lower after reports that Anthropic's Biolab has discovered a new enzyme system that resembles the Crispr gene editing tool.
This headline represents a significant corporate catalyst for CRISPR Therapeutics (CRSP) and the broader gene-editing sector. The discovery of a new, similar enzyme system by Anthr…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
Needham analyst Gil Blum reiterated a 'Buy' rating and maintained an $82 price target for CRISPR Therapeutics. This action signals continued confidence from a prominent analyst in …
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics released extended follow-up data from its Phase 1a clinical trial for CTX310, an investigational gene-editing therapy. The data demonstrated deep and durable re…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
CRISPR Therapeutics shares are trading higher after Citizens reiterated its Market Outperform rating and maintained a $80 price target.
This headline indicates a positive corporate catalyst for CRISPR Therapeutics. The reiteration of an 'Outperform' rating and a substantial price target from a reputable financial i…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Citigroup's analyst Yigal Nochomovitz maintained a 'Buy' rating on CRISPR Therapeutics and raised the price target from $82 to $88. This action signals continued bullish sentiment …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 92
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics announced Q2 earnings that significantly surpassed analyst expectations, with a loss of $(0.94) per share against an estimated $(1.17). More notably, sales reac…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.